Sign in
Virtual Congress
BeiGeneius Webinars
BeiGeneius Resources
About us
beigenemedical.info
Zanubrutinib for the Treatment of Patients With Waldenström Macroglobulinemia: Three Years of Follow‑Up
Back
View
POSTER
06/2020
Download
View
For more information about this resource, please
submit a medical information request.
Rating
Rate this resource
Select a rating
Excellent
Very Good
Average
Poor
Terrible
Related resources
Zanubrutinib in Previously Treated CLL/SLL, MCL, MZL, or WM Intolerant to Ibrutinib/Acalabrutinib
6th ESH Translational Research Conference: Lymphoid Malignancies - Impact of COVID-19 disease and vaccination on management of WM patients
Update on BTK Inhibition in Waldenströms Macroglobulinemia
Back
×
This function is only available for registered users.
Your Benefits of registering:
- Use all service functions directly
- Newsletter registration
- Personal library
Welcome to the BeiGene EU Medical Information Website
This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit
beigene.com
for more information.
I am a Healthcare Professional from:
I am not a healthcare professional
×
You are now leaving the website of BeiGene Europe (beigenemedical.info)
Important notice
This link is provided for information purposes only. Please be aware that, if you click on it, you will leave the BeiGene Europe website, which is directed exclusively at users in Europe. The link will take you to a website owned and operated by an independent party over which BeiGene has no control or influence (“third-party website”).
BeiGene Europe makes no representation that information on the third-party website is appropriate or available for use or access in locations outside the country for which the third-party website is intended. Therefore, BeiGene declines any responsibility for third-party information. BeiGene makes no representation regarding the data usage policies of the third party website and declines any responsibility for the use of personal data by the operator of the third-party website. Please ensure that you belong to the target group of the content provided on third-party website and that your access to it complies with the applicable laws and regulations.
Do you really want to leave the website of BeiGene Europe?
×
You are now leaving the italian website of BeiGene EU.
You are now leaving the italian website of BeiGene EU.
Please check your webbrowser
We noticed that your webrowser doesn't meet the requirements, please upgrade!
OK
